Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis
Clicks: 7
ID: 327235
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.8
/100
7 views
6 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #293 of 334 articles by views in european heart journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 334 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND AND AIMS: Hypertension is a common attributable cause of chronic kidney disease (CKD). Mineralocorticoid receptor overactivation can lead to hypertension and contributes to CKD progression. In FIND-CKD, finerenone reduced kidney function decline in participants with CKD without diabetes. This prespecified FIND-CKD analysis assessed finerenone efficacy and safety in participants with hypertensive nephropathy. METHODS: Adults with estimated glomerular filtration rate (eGFR) 25-<90 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio (UACR) 200-3500 mg/g were randomized 1:1 to once-daily finerenone or placebo. Hypertensive nephropathy was investigator-reported. Total eGFR slope from baseline to Month 32 was assessed, along with a kidney-cardiovascular composite of sustained ≥57% eGFR decline, kidney failure, hospitalization for heart failure, or cardiovascular death. RESULTS: Of 1584 randomized participants, 459 (29.0%) had hypertensive nephropathy. Mean blood pressure (± SD) was 134/80 ± 14/10 mmHg, mean eGFR was 44 ± 15 mL/min/1.73 m2, median UACR was 797 mg/g (Q1, Q3: 566, 1247). In participants with hypertensive nephropathy, finerenone slowed total eGFR decline versus placebo by 0.65 mL/min/1.73 m2/year (95% CI: 0.02, 1.29; P = .044) and was associated with a reduction in composite kidney-cardiovascular outcome events (HR: 0.61; 95% CI: 0.38, 0.99; P = .045). These effects were consistent irrespective of baseline systolic blood pressure (SBP) (P-interaction: eGFR slope, 0.96; composite outcome, 0.91). Finerenone reduced SBP by -3.5 mmHg and UACR by 33% at Month 6 vs placebo. Hyperkalaemia occurred more frequently with finerenone (17.1%) than placebo (9.8%); related discontinuation was uncommon (1.3% vs 0.0%, respectively). CONCLUSIONS: Finerenone slowed eGFR decline and reduced kidney-cardiovascular outcome risk in participants with hypertensive nephropathy, supporting its use in this population. ClinicalTrials.gov registration: NCT05047263.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (61 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W7204729027
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Hiddo J.L. Heerspink, Jelle M. Beernink, Rajiv Agarwal, David Z I Cherney, Carolyn S.P. Lam, Brendon L Neuen, Vlado Perkovic, Katherine R. Tuttle, Pantelis Sarafidis, Rita Birne, Xiangmei Chen, Mads Hornum, Rafael Maldonado, Masaomi Nangaku, Susanne B Nicholas, Atsuki Ohashi, Pablo E. Pérgola, See Cheng Yeo, Niels Jongs, J David Smeijer, Carolina Aldworth, Meike Brinker, Peter Kolkhof, Juliana D Reis, Andrea Scalise, Christoph Wanner |
| Journal | european heart journal |
| Year | 2026 |
| DOI |
10.1093/eurheartj/ehag729
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.